The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma

Not yet recruiting

• Conditions: Multiple Myeloma
• Interventions: Genetic: DNA sequencing

• Registration Number: NCT05331313
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-03
• Study First Submitted: 2022-03-31
• Study First Submitted QC: 2022-04-12
• Last Update Submitted: 2022-04-12
• Study First Posted: 2022-04-15
• Last Update Posted: 2022-04-15
• Study Start: 2022-12-01
• Primary Completion: 2023-12-01
• Study Completion: 2024-08-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• diagnosis of multiple myeloma
• availability of abnormal plasmocytes

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with a diagnosis of multiple myeloma	DNA sequencing	This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.

Primary Outcome Measures

Name	Time	Method
DNA mutations associated with the existence of multiple myeloma	through study completion, an average of 1 year	DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Pierre Benite, France